Daflon

Phase 2Small molecule

UUniversitaire Ziekenhuizen KU Leuven

Daflon is one of 17 small molecule programs targeting Helicobacter Pylori Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Helicobacter Pylori InfectionRecruiting

Helicobacter Pylori InfectionPhase 2

Recruiting

Competition

Competitive Landscape

30 competitors in Helicobacter Pylori Infection

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

14 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

20 3

Flagyl

DDePuy Orthopaedics

Approved

10 4

Nexium

DDexcel Pharma Technologies Ltd.

Approved

9 5

Levaquin

WWim Janssens

Approved

5 6

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

5 7

Achromycin V

WWyeth-Lederle Vaccines

Approved

5 8

Potassium Citrate

MMission Pharmacal

Approved

4 9

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

2 10

Vonoprazan

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Helicobacter Pylori Infection

NCT06546111

Q2 2027

Not yet recruiting

Treatment

NCT06318988

Clinical

Trials by Indication[1]

Treatment2 trials

Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Completed·IInterregional Clinical Diagnostic Center, Russia··NCT04512443·83 enrolled

Outcomes of Different Treatment Options in Chronic Venous Disease

Not yet recruiting·UUniversitaire Ziekenhuizen KU Leuven··NCT06318988·2,000 enrolled

Chronic Venous Insufficiency2 trials

Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)

Unknown status·AAzidus Brasil·Phase 3·NCT01110512·140 enrolled

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

Unknown status·LLaboratório Teuto Brasileiro S/A·Phase 3·NCT01477281·82 enrolled

Helicobacter Pylori Infection1 trial

Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection

Recruiting·SSadat City University·Phase 1/2·NCT06546111·46 enrolled

Polycystic Ovary Syndrome1 trial

Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome

Unknown status·—·Phase 4·NCT06083935·120 enrolled

Efficacy1 trial

Efficacy and Tolerability of the Use of Varicell Compared With Daflon

Unknown status·VVidfarma Indústria de Medicamentos Ltda.·Phase 3·NCT01321619·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Daflon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daflon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daflon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Daflon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Treatment2 trials

Chronic Venous Insufficiency2 trials

Helicobacter Pylori Infection1 trial

Polycystic Ovary Syndrome1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News